- Home
- DAVA vs PSNL Comparison
DAVA vs PSNL Comparison
Compare DAVA & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAVA
- PSNL
- Stock Information
- Founded
- DAVA 2000
- PSNL 2011
- Country
- DAVA United Kingdom
- PSNL United States
- Employees
- DAVA N/A
- PSNL N/A
- Industry
- DAVA EDP Services
- PSNL Medical Specialities
- Sector
- DAVA Technology
- PSNL Health Care
- Exchange
- DAVA Nasdaq
- PSNL Nasdaq
- Market Cap
- DAVA 509.6M
- PSNL 518.8M
- IPO Year
- DAVA 2018
- PSNL 2019
- Fundamental
- Price
- DAVA $9.48
- PSNL $9.78
- Analyst Decision
- DAVA Buy
- PSNL Strong Buy
- Analyst Count
- DAVA 9
- PSNL 5
- Target Price
- DAVA $22.89
- PSNL $8.70
- AVG Volume (30 Days)
- DAVA 952.7K
- PSNL 1.3M
- Earning Date
- DAVA 11-11-2025
- PSNL 11-04-2025
- Dividend Yield
- DAVA N/A
- PSNL N/A
- EPS Growth
- DAVA 24.14
- PSNL N/A
- EPS
- DAVA 0.49
- PSNL N/A
- Revenue
- DAVA $1,058,028,497.00
- PSNL $80,317,000.00
- Revenue This Year
- DAVA N/A
- PSNL N/A
- Revenue Next Year
- DAVA $3.81
- PSNL $29.83
- P/E Ratio
- DAVA $19.18
- PSNL N/A
- Revenue Growth
- DAVA 4.25
- PSNL 0.36
- 52 Week Low
- DAVA $8.17
- PSNL $2.83
- 52 Week High
- DAVA $34.94
- PSNL $10.95
- Technical
- Relative Strength Index (RSI)
- DAVA 50.31
- PSNL 64.92
- Support Level
- DAVA $8.55
- PSNL $8.53
- Resistance Level
- DAVA $9.03
- PSNL $10.95
- Average True Range (ATR)
- DAVA 0.37
- PSNL 0.91
- MACD
- DAVA 0.15
- PSNL 0.05
- Stochastic Oscillator
- DAVA 84.31
- PSNL 67.37
About DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.